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Condensation 
Prophylactic use of aspirin may reduce the risk of both preterm and term preeclampsia 
by delaying the gestational age at delivery with the disease. 
 
Short version of article title 
Aspirin delays the development of preeclampsia. 
 
Implications and Contributions  
A. This is an unplanned secondary analysis of data from the ASPRE trial to explore 
the hypothesis that in women at high-risk of preeclampsia, use of aspirin delays the 
gestational age at delivery with the disease. 
B. In the ASPRE trial treatment with aspirin reduced the incidence of early and preterm 
preeclampsia by about 80% and 60%, respectively, but had no significant effect on the 
incidence of term preeclampsia. We have developed and fitted a model which 
demonstrates that aspirin may prevent both preterm and term preeclampsia and the 
reduction of the latter is by about 40%. However, the overall incidence of term 
preeclampsia is not affected because cases of term preeclampsia prevented are 
countered by cases of preterm preeclampsia that are delayed by the effect of aspirin. 
C. The ASPRE trial data are consistent with the hypothesis that aspirin reduces the 
risk of both preterm and term preeclampsia by delaying the gestational age at delivery 
with PE. 
 
 
  
ABSTRACT 
 
Background: In the Combined Multimarker Screening and Randomized Patient 
Treatment with Aspirin for Evidence-Based Preeclampsia Prevention (ASPRE) trial 
risks of preterm preeclampsia (PE) were obtained from the competing risk model. 
Consenting women with risks of greater than 1 in 100 were randomised to treatment 
with aspirin or placebo. The trial showed strong evidence of an effect (odds ratio 0.38, 
95% confidence interval 0.20 to 0.74) on the incidence of preterm-PE, which was the  
primary outcome of ASPRE. There was a small and insignificant effect on the 
incidence of term-PE which was one of the secondary outcomes (odds ratio 0.95, 95% 
CI 0.64 to 1.39). These differential effects on term and preterm-PE could reflect a 
mechanism in which the action of aspirin is to delay the delivery with PE thereby 
converting what would, without treatment, be preterm-PE to term-PE.   
Objective: To examine the hypothesis that the effect of aspirin is to delay the time of 
delivery with PE. 
Study design: This was an unplanned exploratory analysis of data from the ASPRE 
trial. The delay hypothesis predicts that in groups for which preterm-PE, without 
aspirin, were infrequent relative to term-PE, a reduction in term-PE would be expected 
because few cases of preterm-PE would be converted to term-PE.  In contrast, in 
groups for which preterm-PE were frequent relative to term-PE, the conversion of 
preterm-PE to term-PE by aspirin would reduce or even reverse any effect on the 
incidence term-PE. This is examined using the ASPRE trial data by analysis of the 
effect of aspirin on the incidence of term-PE stratified according to the risk of preterm-
PE at randomization. Given that women were included in ASPRE with risks of preterm 
PE > 1 in 100, a risk cut-off if 1 in 50 was used to define higher risk and lower risk 
strata. A statistical model in which the effect of aspirin is to delay the gestational age 
at delivery was fitted to the ASPRE trial data and the consistency of the predictions 
from this model with the observed incidence was demonstrated.  
Results: In the lower risk group (<1 in 50), there was a reduction in the incidence of 
term-PE (odds ratio 0.62, 95% confidence interval 0.29 to 1.30). In contrast, in the 
higher risk group (≥1 in 50) there was a small increase in the incidence of term-PE 
(odds ratio 1.11, 95% confidence interval 0.71 to 1.75). Although these effects fail to 
achieve significance, they are consistent with the delay hypothesis. Within the 
framework of the aspirin-related delay hypothesis, the effect of aspirin was to delay 
the gestational age at delivery with PE by an estimated 4.4 weeks (95% CI 1.4 to 7.1 
weeks) for those that in the placebo group would be delivered at 24 weeks and the 
effect decreased by an estimated 0.23 weeks (95% CI 0.021 to 0.40 weeks) for each 
week of gestation so that at  40+0 weeks the estimated delay was by 0.8 weeks (95% 
confidence interval -0.03 to 1.7 weeks).  
onclusions: The ASPRE trial data are consistent with the hypothesis that aspirin delays 
the gestational age at delivery with PE. 
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INTRODUCTION 
 
In the Combined Multimarker Screening and Randomized Patient Treatment with 
Aspirin for Evidence-Based Preeclampsia Prevention (ASPRE) trial, singleton 
pregnancies identified through screening at 11-13 weeks’ gestation by a combination 
of maternal factors and biomarkers as being at high-risk of PE, were randomized to 
receive aspirin (150 mg per day) vs. placebo from 11 to 14 until 36 weeks’ gestation.1 
Treatment with aspirin reduced the rate of preterm-PE, with delivery before 37 weeks’ 
gestation, (odds ratio 0.38, 95% confidence interval 0.20 to 0.74), but there was no 
significant effect on the incidence of term-PE (odds ratio 0.95, 95% CI 0.64 to 1.39). 
 
It is uncertain whether preterm-PE and term-PE have different pathogenetic 
mechanisms or are merely gradations of the same underlying condition.2 Similarly, the 
mechanism of action of aspirin in preventing PE is uncertain. One explanation for the 
results of the ASPRE trial is that the pathophysiology of preterm-PE and term-PE is 
different and that only the former is susceptible to the preventative effects of aspirin. 
An alternative hypothesis is that aspirin reduces the risk of both preterm-PE and term-
PE and its effect is to delay the gestational age at delivery with PE so that some cases 
of term-PE that are prevented are replaced by cases of preterm-PE; consequently, the 
incidence of term-PE  is increased by shifts from preterm PE to term PE countering 
the effects of aspirin in preventing term-PE. 
 
The objective of this study is to examine whether an aspirin-related delay in the 
gestational age at delivery with PE could explain the findings of the ASPRE trial. 
 
MATERIALS AND METHODS 
 
The ASPRE trial was conducted at 13 maternity hospitals in the United Kingdom, 
Spain, Italy, Belgium, Greece, and Israel.1 In the 13 participating hospitals routine 
screening for preterm-PE was carried out at 11-13 weeks’ gestation by an algorithm 
combining maternal demographic characteristics and medical and obstetrical history,3-
5 with the measurements of mean arterial pressure,6 uterine artery pulsatility index7 
and serum pregnancy associated plasma protein-A and placental growth factor 
(PAPP-A and PlGF 1-2-3TM kits, DELFIA® Xpress random access platform; 
PerkinElmer Inc. Wallac Oy, P.O.Box 10, 20101 Turku, Finland). The eligibility criteria 
for the trial were maternal age >18 years, no serious mental illness or learning 
difficulties, singleton pregnancy with live fetus with no major abnormality demonstrated 
on the 11-13 weeks scan and estimated risk for preterm-PE of >1 in 100.4 Approval 
for the trial was obtained from the relevant research ethics committee and competent 
authority in each country in which the trial was conducted. 
 
Preeclampsia was defined according to the International Society for the Study of 
Hypertension in Pregnancy.8 The systolic blood pressure should be >140 mmHg 
and/or the diastolic blood pressure should be >90 mmHg on at least two occasions 
four hours apart developing after 20 weeks of gestation in previously normotensive 
women. Hypertension should be accompanied by proteinuria of >300 mg in 24 hours 
or two readings of at least ++ on dipstick analysis of midstream or catheter urine 
specimens if no 24-hour collection is available. In PE superimposed on chronic 
hypertension significant proteinuria (as defined above) should develop after 20 weeks 
of gestation in women with known chronic hypertension.  
 Statistical analyses 
 
This is an unplanned secondary analysis of data from the ASPRE trial. In ASPRE, the 
patient-specific risk for PE was estimated by the competing risks approach.3,4 In this 
approach it is assumed that if the pregnancy was to continue indefinitely all women 
would develop PE and whether they do so or not before a specified gestational age 
depends on competition between delivery before or after development of PE. The 
effects of variables from maternal demographic characteristics, medical history and 
biomarkers is to modify the distribution of gestational age at delivery with PE so that 
in pregnancies at low risk for PE the gestational age distribution is shifted to the right 
with the implication that in most pregnancies delivery will actually occur before 
development of PE. In high-risk pregnancies the distribution is shifted to the left and 
the smaller the mean gestational age the higher is the risk for PE.  
Subgroup Analysis – Stratification by risk of preterm PE 
The prevention of term-PE and the transition from preterm-PE to term-PE was 
explored by analysis of the effect of aspirin on the incidence term-PE stratified 
according to risk of preterm-PE at randomization. Given that women were included in 
ASPRE with risks of preterm PE > 1 in 100, a risk cut-off of 1 in 50 was used to define 
higher risk and lower risk strata.  Estimates and confidence intervals for the effect on 
term-PE in the higher and lower risk groups were obtained by fitting separate mixed 
effects logistic regression models with fixed effects for treatment and for the logistic 
transformation of risk of preterm-PE and random effects for participating centre. 
Aspirin-related shift model 
The analysis explores the hypothesis that aspirin shifts the distribution time to delivery 
with PE. We postulate that, if T denotes the random variable representing the 
gestational age at delivery with PE in the placebo group, the effect of aspirin is a delay 
of  shifting the distribution to that of T + .  In randomized controlled trials, where 
there is no censoring, this model is used extensively with t-tests being applied to test 
the null hypothesis that  = 0.  In applications to PE, the same model can be applied 
but the analysis needs to take account of censoring using a survival time model. In 
terms of the conventional classification of preterm-PE (T < 37 weeks) and term-PE (T 
≥ 37 weeks), the effect would be to prevent some term-PE because birth for other 
causes would occur prior to PE. However, for some women delays to preterm-PE 
would lead to term-PE.  
 
We fitted a model to reflect the hypothesis of an aspirin-related shift effect 
with  decreasing with gestational age, so that the magnitude of the delay in 
gestational age at delivery with PE is greater at earlier than later gestational ages 
(Figure 1).  
 
We assumed a Gaussian distribution for T in the placebo group with a mean 
dependent of the logit of the risk according to a linear regression model and a constant 
standard deviation σ.  In the aspirin group, the same model was used but T was 
increased by the treatment effect   = β0+β1(T -24).  With this parameterisation β0 
represents the effect of aspirin at 24 weeks gestation.  For every week of gestation 
after 24 weeks, this the effect is reduced by -β1.  The standard deviation in the aspirin 
group is (1 +β1) σ. 
Using a non-informative prior distribution for unknown parameters, the aspirin-related 
shift model was fitted within a Bayesian framework using Markov chain Monte Carlo 
(MCMC) implemented inWinBUGS.9 Inferences for model parameters are presented 
in terms of posterior means, standard deviations and 95% credibility 
intervals. Samples from the posterior predictive distribution were used to simulate 
ASPRE outcome data as follows. Samples of 5,000 observations of the model 
parameters were taken from the MCMC iterations. For each of these, the gestational 
ages at delivery with PE were generated for the 1,620 trial participants for both the 
aspirin and placebo treatments. Gestational ages at births due to other causes were 
obtained by sampling with replacement from the gestational ages at birth due to other 
causes from the ASPRE trial. PE events were then defined according to whether the 
gestational age at delivery with PE was younger than the gestational age due to births 
from other causes. This provided 5,000 samples from the posterior predictive 
distribution of data from the ASPRE trial under the assumption of the model.  
 
As described above WinBUGS9 as used for model fitting, the statistical software R 
was used for data analyses.10  
 
RESULTS  
 
The distribution of gestational age at delivery with PE in the placebo and aspirin groups 
is shown in Figure 2, which demonstrates that in the aspirin group the incidence of 
early deliveries with PE is reduced.    
 
A subgroup analysis of incidence of preterm-PE and term-PE is given in Table 1. The 
higher risk group contains those with risks of preterm-PE of ≥1 in 50 and the lower risk 
group those with risks of <1 in 50.  In the higher risk placebo group the ratio of term-
PE to preterm-PE is 41 to 31 (1.3 to 1) compared to a ratio of 18 to 4 (4.5 to 1) in the 
lower risk group. Therefore, in the higher risk group there are relatively more cases of 
preterm-PE that could, with aspirin, convert to term-PE than in the lower risk group. 
These transitions from preterm-PE to term-PE would counteract cases of term-PE 
prevented by aspirin. In contrast, in the lower risk group, there are relatively few cases 
of preterm-PE that could be converted to term-PE. As expected under the hypothesis 
of the shift model, there was a larger decrease in incidence of term-PE in the lower 
risk group (Figure 3). In the lower risk group there was a reduction in the incidence of 
term-PE (odds ratio 0.62, 95% confidence interval 0.29 to 1.30), whereas in the higher 
risk group there was a small but insignificant increase in the incidence of term-PE 
(odds ratio 1.11, 95% confidence interval 0.71 to 1.75).  
 
In the survival analysis, 90% of observations were censored, 92% in the aspirin group 
and 88% in the placebo group. Parameter estimates from the aspirin-related shift 
model are shown in Table 2. The effect of aspirin treatment was to delay the 
gestational age at delivery with PE by an estimated 4.4 weeks (95% credibility interval 
1.4 to 7.1 weeks) for those that in the placebo group would be delivered at 24 weeks. 
This effect decreased by an estimated 0.23 weeks (95% credibility interval 0.02 to 0.40 
weeks) for each week of gestation (Figure 4) and at 40+0 weeks, the estimated effect 
was a delay by 0.8 weeks (95% credibility interval -0.03 to 1.7 weeks). The observed 
number of cases of PE with delivery at <34, 34+0 to 36+6 and ≥37 weeks’ gestation in 
the aspirin and placebo groups and summaries of samples from the posterior 
predictive distribution (mean, 2.5th and 97.5th percentiles) are shown in Table 3. The 
data of samples from the posterior predictive distribution are consistent with the 
observed data and this provides support for the aspirin-related shift hypothesis. 
 
COMMENT 
 
In the ASPRE trial treatment with aspirin reduced the incidence of PE with delivery 
<32, <34, <37 weeks’ gestation by about 90%, 80% and 60%, respectively, but had 
no significant effect on the incidence of term-PE.1 The findings of this post hoc 
exploratory analysis of data from the ASPRE trial are consistent with the hypothesis 
that the mechanism of action of aspirin is to delay the gestational age at delivery with 
PE.  
 
We have developed and fitted a model that reflects the hypothesis of an aspirin-related 
shift effect so that the magnitude of the delay in gestational age at delivery with PE is 
greater at earlier than later gestational ages and have demonstrated that this model 
predicts the incidence data in the ASPRE trial. According to this model, aspirin 
prevents both preterm-PE and term-PE and the reduction of the latter is by about 40%. 
However, much of term-PE prevented is replaced by term-PE that results from the 
effect of aspirin in delaying the need for preterm delivery with PE. This model therefore 
explains the findings from ASPRE that treatment with aspirin leads to substantial 
reduction in the incidence of preterm-PE but has little effect on the incidence of term-
PE.   
 
In contrast to previous approaches to prediction of PE which treat preterm-PE and 
term-PE as different conditions11-14 we have developed and validated prediction 
models for the gestational age at delivery with PE.3-5 In this paper, we have applied 
the same logic to the analysis of the effect of aspirin and demonstrated that the data 
from ASPRE are consistent with the hypothesis that aspirin delays the gestational age 
at delivery with PE in a way that has a larger effect for deliveries that would, without 
treatment, occur at earlier gestations.  Within the context of this model, the incidence 
of deliveries with PE at term is increased by the effects of delays to preterm-PE.  
 
This hypothesis generating unplanned exploratory analysis of the ASPRE trial data 
does not have sufficient power for any firm conclusions to be drawn from the subgroup 
analysis of term-PE. All we would claim in this paper is that the delay hypothesis is an 
empirically valid and clinically plausible mechanism.  In interpretation of studies such 
as ASPRE, it is important to recognize that reductions in preterm-PE might counter or 
even reverse any effects on the incidence of term-PE.   
  
FIGURE LEGENDS 
Figure 1: Effect of aspirin in delaying the gestational age at delivery with 
preeclampsia. 
Figure 2: Distribution of gestational age at delivery with preeclampsia in the placebo 
and aspirin groups in the ASPRE trial. This demonstrates that in the aspirin group the 
incidence of early deliveries with PE is reduced.    
Figure 3: Odds ratios (aspirin/placebo) and 95% confidence intervals for the effect of 
aspirin on term preeclampsia. As expected under the hypothesis of the shift model, 
there was a larger decrease in incidence of term preeclampsia in the lower risk group. 
Figure 4: Fitted model for the effect of aspirin in delaying gestation at delivery with 
preeclampsia (black line) with 95% credibility intervals (black interrupted lines). The 
aspirin-related delay was greater for earlier than later preeclampsia.  
Table 1: Incidence of preterm-PE and term-PE in the aspirin and placebo groups 
stratified by risk. 
 
 Risk of preterm-PE  
Treatment 
group 
 
PE < 37 w PE ≥ 37 w No PE 
Total n n n 
≥1 in 50 
 
Aspirin 11 (2.7%) 41 (8.8%) 412 (88.8%) 464 
Placebo 31 (7.1%) 41 (8.1%) 435 (85.8%) 507 
<1 in 50  Aspirin 2 (0.6%) 12 (3.6%) 320 (95.8%) 334 
Placebo 4 (1.4%) 18 (5.7%) 293 (93.0%) 315 
All Aspirin 13 (1.8%) 53 (6.6%) 732 (91.7%) 798 
Placebo 35 (4.8%) 59 (7.2%) 728 (88.6%) 822 
 
  
Table 2: Posterior means and 95% confidence interval for parameters from the 
aspirin-related shift model.  
 
Coefficient 
Estimate (95% confidence 
interval) 
Constant 38.95 (37.43,  40.54) 
logit(risk) -2.35 (-2.912,  -1.85) 
Aspirin 4.4 (1.4,  7.1) 
Aspirin*(gestational age – 24 weeks) -0.23 (-0.02,  -0.40) 
Standard deviation 5.838 (4.973,  6.857) 
 
Table 3: Observed number of cases of preeclampsia with delivery at <34, 34+0 to 36+6 
and ≥37 weeks’ gestation in the aspirin and placebo groups from the ASPRE trial and 
summaries of samples from the posterior predictive distribution (mean, 2.5th and 97.5th 
percentiles). 
 
 
 
  
  Number of cases delivering with preeclampsia  
Aspirin group (n=798) < 34 w 34+0 to 36+6 w ≥ 37 w None 
Observed 3 10 53 732 
Predicted model  4.9 (1, 11) 16.4 (8, 26) 44.1 (29, 62) 732.5 (711, 752) 
Placebo group (n=822)     
Observed 15 20 59 728 
Predicted model  16.9 (8, 26) 27.6 (17, 39) 49.3 (34, 67) 728.3 (703, 751) 
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